American Nimodipine Study "ANS"

Completed

Phase 3 Results

Summary of Purpose

To test the hypothesis that nimodipine would reduce the frequency of death and of worsening by 30% compared with placebo.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 10 October 2000.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Miles Inc., Bayer AG, the Horace W. Goldsmith Foundation, and the Remin Fund

Trial Design

Randomized, double-blind, multicenter clinical trial of 1,064 patients.

Contacts

Not available